Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN® or TRAVATAN®

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 2, 2010, Pages 147-156

  Faulkner, Robert ^a   Sharif, Najam A ^a   Orr, Susan ^a   Sall, Kenneth ^b   Dubiner, Harvey ^c   Whitson, Jess T ^d   Moster, Marlene ^e   Craven, E Randy ^f   Curtis, Michael ^a   Pailliotet, Cynthia ^a   Martens, Kimberly ^a   Dahlin, David ^a  

^a ALCON RESEARCH LTD   (United States)

^b Sall Eye Research Medical Center   (United States)

^c Clayton Eye Center   (Georgia)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e WILLS EYE HOSPITAL   (United States)

^f Private Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; TRAVOPROST;

ADULT; AQUEOUS HUMOR; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENCY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PARACENTESIS;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CATARACT EXTRACTION; CHROMATOGRAPHY, LIQUID; CLOPROSTENOL; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; TANDEM MASS SPECTROMETRY;

EID: 77951680617     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0098     Document Type: Article

References (72)

1. Sharif, N.A., Klimko, P. CNS: Ophthalmic Agents, in Comprehensive Medicinal Chemistry II., 2007; Vol.6, Chapter 12, p297-320 (Eds: J.B. Taylor & D.J. Triggle), Elsevier, Oxford, UK
2. Martínez-Belló, C., Chauhan, B. C., Nicolela, M. T., et al. Intraocular pressure and progression of glaucomatous visual fi eld loss. Am. J. Ophthalmol. 129: 302-308, 2000. (Pubitemid 30126074)
3. Camras, C. B. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv. Prostaglandin Thromboxane Leukot. Res. 23: 519-525, 1995.
4. Bito, L. Z., and Baroody, R. A. The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PFG2 alpha-1-isopropyl ester. Exp. Eye Res. 44: 217-226, 1987.
5. Madhu, C., Rix, P., Nguyen, T., et al. Penetration of natural prostaglandins and their ester prodrugs and analogs across human ocular tissues in vitro. J. Ocul. Pharmacol. Ther. 14: 389-399, 1998 (Pubitemid 28489681)
6. Stjernschantz, J., Selen, G., Sjöquist, B., et al. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF 2α analogue. Adv. Prostaglandin. Thrombox. Leukotr. Res. 23: 513-518, 1995.
7. Woodward, D., Krauss, A., and Chen, J. Replacement of the carboxylic acid group of prostaglandin PGF 2α with a hydroxyl or methoxy substituent provides biologically unique compounds. Br. J. Pharmacol. 130: 1933-1943, 2000. (Pubitemid 30657505)
8. Whitson, J. T. Travoprost\a new prostaglandin analogue for the treatment of glaucoma. Expert. Opin. Pharmacother. 3: 965-977, 2002. (Pubitemid 34752514)
9. Lim, K., Nau, C., O'Byrne, M., et al (Pubitemid 351602291)
10. Ocklind, A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp. Eye Res. 67: 179-191, 1998. (Pubitemid 28428266)
11. Schachtschabel U., Lindsey, J., and Weinreb, R (Pubitemid 30164031)
12. Kashiwagi, J. M., Suzuki, M., Tanaka, Y., et al. Isopropyl unoprostone increases the activities of matrix metalloproteinases in cultured monkey ciliary muscle cells. J. Glaucoma. 10: 271-276, 2001. (Pubitemid 32781341)
13. Gabelt, B., and Kaufman, P. Prostaglandin F2 alpha increases uveoscleral outfl ow in the cynomologus monkey. Exp. Eye Res. 49: 389-402, 1989. (Pubitemid 19239397)
14. Nilsson, S The Uveoscleral Outfl Ow Routes. Eye. 11: 149-154, 1997.
15. Weinreb, R., Toris, C., Gabelt, B., et al. Effects of prostaglandins on the aqueous humor outfl ow pathways. Surv. Ophthalmol. 47 (Suppl 1): S53-S64, 2002. (Pubitemid 35232219)
16. Sagara, T., Gaton, D., Lindsey, J., et al. Topical Prostaglandin F2 alpha treatment reduces collagen types I, III and IV in the monkey uveoscleral outfl ow pathway. Arch Ophthalmol. 117: 794-801.
17. Toris, C. B., Camras, C., Yablonski, M., et al. Effects of exogenous prostaglandins on aqueous humor dynamics and bloodaqueous barrier function. Surv. Ophthalmol. 41 (Suppl 2): S69-S75, 1997. (Pubitemid 27154527)
18. Hellberg, M. R., McLaughlin, M. A., Sharif, N. A., et al. Identifi cation and characterization of the ocular hypotensive effi cacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv. Ophthalmol. 47 (Suppl #1): S13-S33, 2002.
19. Sharif, N. A., Kelly, C. R., and Crider, J. Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmol. Vis. Sci. 44: 715-721, 2003.
20. Shen, Y. W., and Tao, R. V. The presence of ceramide hydrolase and synthethase in pig lens epithelium. Invest. Ophthalmol. Vis. Res. 22: 734-743, 1982.
21. Matsuda, S., Kanemitsu, N., Nakamura, A., et al. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Exp. Eye Res. 64: 707-711, 1997. (Pubitemid 27278298)
22. Startford, R. E., Jr., and Lee, V. H. Ocular aminopeptidase activity and distribution in the albino rabbit. Curr. Eye Res. 4: 995-999, 1985.
23. Sharif, N.A., Davis, T.L., and Williams, G.W. [3 H]AL-5848 (9-β-[+] fl uprostenol): carboxylic acid of Travoprost (AL-6221), a novel FP-prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J. Pharmacy Pharmacol. 51: 685-1594, 1999.
24. Sharif, N. A., Crider, J. Y., Husain, S., et al. Human ciliary muscle responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J. Ocul. Pharmacol. Ther. 19: 437-455, 2003. (Pubitemid 37315132)
25. Sharif, N. A., Kelly, C. R., and Crider, J. Y. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J. Ocul. Pharmacol. Ther. 18: 313-324, 2002.
26. Sharif, N.A., Kelly, C.R., and Williams, G.W. Bimatoprost (Lumigan®) is an agonist at the cloned human ocular FP prostaglandin receptor: real-time FLIPR-based intracellular Ca 2+ mobilization studies. Prost. Leukotr. Essent. Fatty Acids 68: 27-33, 2003.
27. Kelly, C.R., Williams, G.W., and Sharif, N.A. Real-time intracellular Ca 2+-mobilization by travoprost acid, bimatoprost, unoprostone and other analogs via endogenous mouse, rat and cloned human FP prostaglandin receptors. J. Pharmacol. Expt. Ther. 304: 238-245, 2003.
28. Sharif, N.A., Williams, G.W., and Kelly, C.R. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur. J. Pharmacol. 432: 211-213, 2001.
29. Woodward, D. F., Krauss, A. H.-P., Chen, J., et al. The pharmacology of bimatoprost (Lumigan ™). Surv. Ophthalmol. 45 (Suppl. 1): S337-S345, 2001.
30. Woodward, D. F., Krauss, A. H.-P., Chen, J., et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J. Pharmacol. Exp. Ther. 305: 772-785, 2003. (Pubitemid 36459199)
31. Shimura, M., Yasuda, K., Nakzawa, T., et al. The effect of unoprostone isopropyl on Ca2+ release-activated Ca2+ current in cultured monkey trabecular meshwork cells and ciliary muscle cells. J. Ocul. Pharmacol. Ther. 22: 219-226, 2006. (Pubitemid 44689660)
32. Kashiwagi, K., Iizuka, Y., and Tasukahara, S. Metabolites of isopropyl unoprostone as potential ophthalmic solutions to reduce intraocular pressure in pigmented rabbits. Jpn. J. Pharmacol. 81: 56-62, 1999. (Pubitemid 29479055)
33. Taniguchi, T., Haque, M. S. R., Sugiyama, K., et al. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbit. J. Ocul. Pharmacol. 12: 489-498, 1996. (Pubitemid 26405753)
34. Takagi, Y., Nakaj ima, T., Shimazaki, A., et al. Pharmacological characteristics of AFP-168 (tafl uprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp. Eye Res. 78: 767-776, 2004
35. Nakaj ima, T., Matsugi, T., Goto, W., et al. New fl uoroprostaglandin F2 derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol. Pharm. Bull. 26: 1691-1695, 2003. (Pubitemid 39663527)
36. Nedelman, J. R., Gibiansky, E., and Tau, D. T. W. Applying bailer's method for AUC confi dence intervals to sparse sampling. Pharm. Res. 12: 124-128, 1995.
37. Kriatchko, A., Zhan, G., Cheruvu, N., et al. In vitro hydrolysis of bimatoprost in bovine cornea. Assoc. Res. Vis. Res. Abst. # 4422, 2003.
38. Maxey, K. M., Johnson, J. L., and LaBreque, J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv. Ophthalmol. 47 (Suppl 1): S34-S40, 2002.
39. Sharif, N. A., Kelly, C. R., Crider, J. Y., et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affi nities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19: 501-515, 2004
40. Bhattacherj ee, P., Smithson, M., and Paterson, C. A. Generation of second messengers by prostanoids in the iris-sphincter and ciliary muscle of cows, cats and humans. Prostagland. Leukot. Essent. Fatty Acids. 56: 443-449, 1997. (Pubitemid 27276177)
41. Sharif, N. A., Kaddour-Dj ebbar, I., & Abdel-Latif, A. A. Cat iris sphincter smooth muscle contraction: comparison of FP-class prostaglandin analog agonist activities. J. Ocul. Pharmacol. Ther. 24: 152-163, 2008. (Pubitemid 351450472)
42. Hellberg, M. R., Ke, T.-L., Haggard, K., et al. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF 2α by human and rabbit ocular tissues. J. Ocul. Pharmacol. Ther. 19: 97-103, 2003. (Pubitemid 36539135)
43. Abramovitz, M., Boie, Y., Nguyen, T., et al. Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol. Chem. 269: 2632-12626, 1994. (Pubitemid 24196718)
44. Kunapuli, P., Lawson, J., Rokach, J., et al. Functional characterization of the ocular prostaglandin F2alpha (PGF 2α) receptor. J. Biol. Chem. 272: 27147-27154, 1997.
45. Davis, T. L., and Sharif, N. A. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J. Ocul. Pharmacol. Ther. 15: 323-336, 1999.
46. Cantor, L. Clinical pharmacology of bimatoprost. Expert Opin. Drug Metab. Toxicol. 1: 151-157, 2005.
47. Cantor, L. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Exp. Opin. Invest. Drugs. 10: 721-731, 2001. (Pubitemid 32288189)
48. Spada, C. S., Krauss, A. H., Woodward, D. F., et al. Bimatoprost and prostaglandin F2α selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Exp. Eye Res. 80: 135-145, 2005.
49. Krauss, A. H. P., and Woodward, D. F. Update on the mechanism of action of bimatoprost (Lumigan®): discussion of new evidence. Surv. Ophthalmol. 49: (Suppl. 1): S5-S11, 2004.
50. Cantor, L. B., Hoop, J., Wudunn, D., et al. Levels of bimatoprost acid in the aqueous humor after bimatoprost treatment of patients with cataracts. Br. J. Ophthalmol. 91: 629-632, 2007. (Pubitemid 46716532)
51. Camras, C. B., Toris, C. B., Sj öquist, B., et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmol. 111: 2193-2198, 2004.
52. Davies, S. S., Ju, W-K., Neufeld, A. H., et al. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J. Ocul. Pharmacol. Ther. 19: 45-54, 2003.
53. Dahlin, D., Craven, E. R., Moster, M., et al. Human aqueous humor concentrations of bimatoprost and bimatoprost free acid following topical ocular dosing of Lumigan ([Bimatoprost; 17-phenyl-trinor PGF2α ethyl amide] 0.03% ophthalmic solution). Assoc. Res. Vis. Ophthalmol. (ARVO) Abst. # 2096, 2004.
54. Sharif, N. A., Ke, T-L., Haggard, K., et al. Bimatoprost hydrolysis to 17-phenyl-trinor PGF 2α by human and rabbit ocular tissues and agonist activity of bimatoprost and 17-phenyl-trinor PGF2α. Assoc. Res. Vis. Ophthalmol. Abst. #4080, 2002.
55. Calissendorff, B., Sj öquist, B., Högberg, G., et al. Bioavailability in the human eye of a fi xed combination of latanoprost and timolol compared to monotherapy. J. Ocul. Pharmacol. Ther. 18: 127-131, 2002 (Pubitemid 34297296)
56. Sjöquist, B., and Stjernschantz, J. Ocular and systemic pharmacokinetic of latanoprost in humans. Surv. Ophthalmol. 47 (Suppl 1): S6-S12, 2002. (Pubitemid 35232215)
57. Lafuma, D., Khoshnood, B., Mimaud, V., et al. A meta-analysis of topical prostaglandin analogues intraocular pressure lowering in glaucoma therapy. Curr. Med. Res. Opin. 23: 601-608, 2007. (Pubitemid 46456908)
58. Parrish, R., Palmberg, P., and Sheu, W-P. A comparison of latanoprost, bimatoprost and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. 125: 688-703, 2003. (Pubitemid 36457976)
59. Yildirim, N., Sahin, A., and Gultekin, S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J. Glaucoma. 17: 36-39, 2008. (Pubitemid 351321474)
60. Maul, E., Carrasco, F., Costa, V., et al. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin. Ther. 29: 1915-1923, 2007 (Pubitemid 350212801)
61. Sjöquist, B., Basu, S., Byding, P., et al. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab. Dispos. 26: 745-754, 1998. (Pubitemid 28376433)
62. Shimura, M., Yasuda, K., Nakzawa, T., et al. The effect of unoprostone isopropyl on Ca 2+ release-activated Ca 2+ current in cultured monkey trabecular meshwork cells and ciliary muscle cells. J. Ocul. Pharmacol. Ther. 22: 219-226, 2006. (Pubitemid 44689660)
63. Taniguchi, T., Haque, M. S. R., Sugiyama, K., et al. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbit. J. Ocul. Pharmacol. 12: 489-498, 1996. (Pubitemid 26405753)
64. Sponsel, W., Gianmarco, P., Trigo, Y., et al. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma. Am. J. Ophthalmol. 234: 552-559, 2002. (Pubitemid 35304645)
65. Susanna, R., Giampani, J., Borges, A., et al (Pubitemid 32115953)
66. Tsukamoto, H., Mishima, H., Kitazawa, Y., et al. A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension. J. Glaucoma. 11: 497-501, 2002. (Pubitemid 36015108)
67. Susanna, R., Chew, P., and Kitazawa, Y. Current status of prostaglandin therapy; latanoprost and unoprostone. Surv. Ophthalmol. 47 (Suppl 1): S97-S104, 2002. (Pubitemid 35232223)
68. Crowston, J. G., Lindsey, J. D., Morris, C. A., et al. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest. Ophthalmol. Vis. Sci. 46: 4571-4577, 2005.
69. Ota, T., Aihara, M., Narumiya, S., et al. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-defi cient mice. Invest. Ophthalmol. Vis. Sci. 46: 4159-4163, 2005. (Pubitemid 44264618)
70. Crowston, J. G., Lindsey, J. D., Aihara, M., et al. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest. Ophthalmol. Vis. Sci. 45: 3555-3559, 2004. (Pubitemid 39298573)
71. Ota, T., Aihara, M., Saeki, T., et al. The IOP-lowering effects and mechanism of action of tafl uprost in prostanoid-receptor defi-cient mice. Br. J. Ophthalmol. 91: 673-676, 2007. (Pubitemid 46716541)
72. Sharif, N. A., and Klimko, P. Update and commentary on the prodrug bimatoprost and a putative "prostamide receptor." Expert Rev. Ophthalmol. 4: 477-489, 2009.